EMERALD-Y90: Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
Details
Age
Adult
Locations
University of Colorado Hospital
Principal Investigator
Jonathan Lindquist
Study ID
Protocol Number: 23-1827
More information available at ClinicalTrials.gov: NCT06040099
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers